Cellect upbeat on year ahead after FDA hires

23 January 2019

Israeli cell therapy company Cellect Biotechnology (Nasdaq: APOP) has been given confidence in its ability to progress its goals rapidly by the US Food and Drug Administration’s (FDA) hiring of 50 new clinical reviewers who specialize in this area.

Chief executive Shai Yarkoni expects 2019 to be a significant year for Cellect and the progression of its global clinical development program.

He said: “I believe the special attention and resources being allocated by the FDA will allow us to further advance our cell therapy programs as we intend to submit an IND for a Phase I/II study in the USA and an IDE for our second product (the Apotainer) and complete the preclinical effort towards a third indication by the end of 2019."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK